Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy
Year: 2026
Type: article
Abstract: AIMS: Chronic kidney disease (CKD) is associated with uraemic cardiomyopathy characterized by early metabolic dysfunction. Elevated myocardial intracellular sodium (Naᵢ) has emerged as a driver of cardiometabolic remodelling, however, its role in CKD and therapeutic modulation remains unclear. We investigated whether dual sodium-glucose cotransporter (SGLT)1/2 inhibition with sotagliflozin (SOTA) targets Naᵢ and improves cardiac metabolism in CKD. METHODS AND RESULTS: CKD was induced in male Wistar rats by 5/6 nephrectomy and assessed after 4 weeks. Cardiac phenotype was evaluated using in vivo echocardiography and ex vivo Langendorff perfusion combined with 23Na and 31P NMR spectroscopy. CKD hearts exhibited preserved systolic but impaired diastolic function and a marked elevation in myocardial Naᵢ, identifying Naᵢ overload as an early feature of uraemic cardiomyopathy. Cardiac metabolomic profiling and flux modelling demonstrated widespread suppression of central carbon metabolism, redox imbalance despite preserved PCr/ATP. In silico electrophysiological simulations predicted Naᵢ-driven Ca2+ dysregulation consistent with in vivo diastolic dysfunction. Chronic SOTA treatment (3 weeks, in vivo) normalized myocardial Naᵢ and partially reversed metabolic remodelling. Acute SOTA exposure (20 min, Langendorff-perfusion) similarly reduced Naᵢ in CKD hearts but not in controls, indicating a direct, disease-selective myocardial effect. Naᵢ normalization was accompanied by improved redox state and restoration of mitochondrial metabolic flux, without changes in expression of canonical Na + -handling proteins. CONCLUSION: Myocardial Naᵢ overload emerges as an early and potentially modifiable feature of uraemic cardiomyopathy. Dual SGLT1/2 inhibition with SOTA directly lowers Naᵢ and improves cardiac metabolic homeostasis, supporting Naᵢ as a mechanistically relevant and potentially targetable pathway in CKD-related cardiac remodelling.
Source: Cardiovascular Research
DOI: 10.1093/cvr/cvag167
Authors: Megan Young, Anja Karlstaedt, Sanushi Dambure, Jack J J J Miller, Tong Guo, Xin Zhou, Zenouska Ramchunder, Jair Gonzalez Marques Junior, Muriel Nobles, Andrew Tinker, Kyuongmin Kim, Amanda R Purcell, Sarah J Glastras, Fenn Cullen, Thomas R Eykyn, Alex Von Kriegsheim, Blanca Rodriguez, Michelangelo Campanella, Michael J Shattock, Nay Aung, Claudia P Cabrera, Magdi M Yaqoob, Dunja Aksentijevic
Institutions: Queen Mary University of London, William Harvey Research Institute, Cedars-Sinai Medical Center, Cedars-Sinai Smidt Heart Institute, Aarhus University, University of Oxford, Edinburgh Cancer Research, Institute of Genetics and Cancer, University of Edinburgh, The University of Sydney, St Thomas' Hospital, King's College London, British Heart Foundation, Centre National de la Recherche Scientifique, University of Padua, Institut Gustave Roussy, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, National Institute for Health and Care Research
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,329
Funders: Bristol-Myers Squibb, Queen Mary University of London, Wellcome Trust, UK Research and Innovation, Barts Charity, NoVo Foundation, National Institute for Health and Care Research, British Heart Foundation, King's College London, Queen Mary, University of London, European Cooperation in Science and Technology, Ministero dell’Istruzione, dell’Università e della Ricerca, Fondation ARC pour la Recherche sur le Cancer, Associazione Italiana per la Ricerca sul Cancro, National Institutes of Health, Directorate for Biological Sciences, Medical Research Council, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, European Research Council, National Heart, Lung, and Blood Institute
Awards: G1211483440, King's College London Medical Engineering Centre of Research Excellence, G1380310886, G1688297280, G1843211278, G1904256742, G194540006, G2570888512, G3103330169, G3693129563, Immunometabolic cross-talk in the inflamed diabetic heart, Enabling technologies, Funding to support the purchase of 800MHz and 600MHz spectrometers and resources for automation in the Centre for Biomolecular Spectroscopy (Joint funding with Wellcome Trust), G490430286, Human in silico clinical trials in post myocardial infarction: mechanistic investigations into phenotypic electromechanical variability and response to treatment, G5156429037, G5301227369, King's College London Medical Engineering Centre of Research Excellence, G5935007269, G6628349787, G6721460743, Human in silico clinical trials in post myocardial infarction: mechanistic investigations into phenotypic electromechanical variability and response to treatment, King’s NMR Facility for structural biology, metabolic profiling and drug discovery, Regulation of cardiac metabolism during Leukemia, G9000922310
OpenAlex ID: W7202209086
